iShares Neuroscience and Healthcare ETF
IBRN
2 hedge funds and large institutions have $4.35M invested in iShares Neuroscience and Healthcare ETF in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.93% less ownership
Funds ownership: 92.03% → 91.1% (-0.93%)
9% less capital invested
Capital invested by funds: $4.79M → $4.35M (-$441K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
+$79.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$127K |
IBRN Hedge Fund Activity: Q1 2023 in Review
2 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in iShares Neuroscience and Healthcare ETF (IBRN) for Q1 2023, worth a combined $4.35M — down 9.2% from $4.79M a quarter earlier.
Fund positioning in IBRN was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Flow Traders U.S., adding an estimated $79.7K. The largest seller was BlackRock, cutting an estimated $127K.
- 2 institutional investors held iShares Neuroscience and Healthcare ETF (IBRN) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $4.35M of iShares Neuroscience and Healthcare ETF stock for Q1 2023, down 9.2% quarter-over-quarter.
- 0 funds opened new iShares Neuroscience and Healthcare ETF positions in Q1 2023 and 0 closed out.
- The largest iShares Neuroscience and Healthcare ETF buyer in Q1 2023 was Flow Traders U.S., an estimated $79.7K added.
- The largest iShares Neuroscience and Healthcare ETF seller in Q1 2023 was BlackRock, an estimated $127K sold.
Based on aggregated 13F filings for Q1 2023.